Cartilage Mesenchymal Stromal Cells for Knee Osteoarthritis: Adjunctive Use

Knee osteoarthritis (OA) is a progressive joint disease characterized by articular cartilage degradation, subchondral bone remodeling, and chronic low‑grade inflammation. Current standard management includes physical therapy, weight management, analgesics, and intra‑articular injections, yet many patients experience persistent symptoms. Recent research has explored the adjunctive use of mesenchymal stromal cells (MSCs) as a supportive strategy to modulate joint homeostasis (Freitag et al., 2020).

Growing Interest in Cell‑Based Adjunctive Options for Knee OA

Over recent years, both patient and clinician interest in regenerative adjunctive therapies for knee osteoarthritis has grown, reflecting a desire for approaches that target underlying biological processes alongside rehabilitation and nutrition. Public search trends and registry analyses indicate that individuals with early‑to‑moderate knee OA frequently seek supportive options that may complement conventional physiotherapy. Within a functional medicine framework, MSC therapy is positioned as an investigational adjunct — not a replacement — for structured exercise programs and anti‑inflammatory dietary patterns (ISSCR, 2025).

Current Evidence from Phase I/II Trials: Safety Profile and Symptomatic Signals

Current evidence from phase I/II trials and case series suggests that intra‑articular administration of umbilical cord‑derived MSCs (UC‑MSCs) is associated with a favorable safety profile in knee OA. A 2023 systematic review of 15 early‑phase studies (n=412 participants) reported that adverse events were generally mild and transient — primarily local pain or swelling — with no serious treatment‑related complications (Song et al., 2023). Symptomatic benefit remains under investigation; some small trials have observed trends toward reduced pain scores and improved functional outcomes at 6‑12 months, but controlled studies with larger cohorts are needed to confirm efficacy.

Researchers hypothesize that MSCs exert paracrine effects, including immunomodulation and secretion of trophic factors that may support cartilage homeostasis. However, conclusive evidence for structural cartilage regeneration is lacking. As the American Academy of Orthopaedic Surgeons (AAOS, 2024) notes, MSC therapies for knee OA are still adjunctive and not standard of care.

"Available phase I/II data indicate an acceptable safety profile for UC‑MSCs in knee OA, but well‑powered randomized trials are required to clarify symptomatic and structural outcomes."

UC‑MSCs within an Integral Medicine Framework: Rehabilitation and Nutrition

An integral (functional) medicine approach to knee osteoarthritis emphasizes multimodal supportive care: individualized physical therapy to strengthen peri‑articular muscles, neuromuscular re‑education, and nutritional interventions such as omega‑3 fatty acids, vitamin D optimization, and weight management. Within this framework, umbilical cord‑derived MSCs are being investigated as a potential adjunct that might favorably modulate the inflammatory joint environment. Preclinical observations suggest that UC‑MSCs may reduce synovitis and shift macrophage polarization toward a regulatory phenotype, potentially creating a more receptive milieu for rehabilitation (Wang & Xu, 2022).

Nevertheless, clinical adoption remains early; the role of UC‑MSCs is strictly adjunctive and should never delay or replace proven conservative measures. Patients are encouraged to continue physical therapy and dietary modifications under medical guidance.

Ongoing Controlled Studies and Cautious Outlook

As of March 2026, several randomized, sham‑controlled trials are actively recruiting (e.g., NCT04919109, NCT05201963) to evaluate UC‑MSCs versus placebo in knee OA, with follow‑up extending to 24 months. These studies will provide higher‑quality data on patient‑reported outcomes, objective functional measures, and cartilage volume via MRI. Until such evidence is available, MSC therapies remain adjunctive and are not approved by the FDA or COFEPRIS for knee OA treatment. Participation in registered clinical trials is the recommended pathway.